Publications by authors named "A Marchesoni"
Objectives: The purpose of this study was to evaluate the performance of a dermatologist-filled-in 7-item questionnaire (called HERACLES) as a screening tool for psoriatic arthritis (PsA) in patients with psoriasis.
Methods: This study was performed in Italy in seven dermatology centres cooperating with rheumatology centres. Adults with psoriasis were consecutively recruited up to a calculated number of 750.
Article Synopsis
- The study investigates treatment options for patients with psoriatic arthritis (PsA) who have not responded to one type of medication, focusing on the effectiveness of two strategies: cycling between TNFi drugs and swapping between TNFi and IL17i drugs.
- It included 122 patients treated with either TNFi or IL17i between January 2016 and January 2022, analyzing their drug retention rates using methods like Kaplan-Meier and Cox regression.
- Results showed that the retention rates were highest for patients who swapped from TNFi to IL17i (58%), compared to cycling TNFi (51%) and swapping from IL17i to TNFi (34%), suggesting that the swap strategy may be more effective for maintaining treatment
Objectives: to evaluate over a 48-month follow-up period the: 1) long-term effectiveness and safety; 2) drug retention rate (DRR); 3) impact of comorbidities and bDMARDs line on MDA and DAPSA remission/low disease activity (LDA) of secukinumab in a multicenter Italian cohort of PsA patients.
Methods: Consecutive PsA patients receiving secukinumab were followed prospectively in Italian centers between 2016 and 2023. Disease characteristics, previous/ongoing treatments, comorbidities and follow-up duration were recorded.
Objectives: This study aims to evaluate in a real-life Italian multicenter cohort of axial spondyloarthritis (axSpA) (1) the 4-year effectiveness and safety of secukinumab, (2) the drug retention rate (DRR), and (3) the impact of the line of bDMARDs treatment, subtype of axSpA, and sex on achieving low disease activity (LDA) and very low disease activity (VLDA).
Methods: Consecutive axSpA patients receiving secukinumab between 2016 and 2023 were prospectively evaluated. Data on disease characteristics, previous/ongoing treatments, comorbidities, and follow-up duration were collected.
Article Synopsis
- The study aimed to evaluate the effectiveness of upadacitinib 15 mg daily in reducing enthesitis in psoriatic arthritis patients, comparing it to placebo and adalimumab through specific clinical trials.
- Results showed that after 24 weeks, UPA15 significantly improved enthesitis resolution and scores on the Leeds Enthesitis Index and SPARCC index compared to placebo, with lasting benefits observed up to 56 weeks.
- UPA15 demonstrated early improvements by 12 weeks, with over 90% of initially enthesitis-free patients remaining so, and it effectively prevented recurrence in over 80% of those who had previously experienced enthesitis.